REXAHN PHARMACEUTICALS | 0,255 Euro | -0,036 -12,37 % | |
| WKN: A0Q3QD ISIN: US7616401011 Ticker-Symbol: R3X | Frankfurt | 25.05.12 | 18:26 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 17.05. | Rexahn Pharmaceuticals: Update On Cancer Drugs | - | Seeking Alpha | |
| 08.05. | Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA | 27 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing potential best in
class oncology and CNS therapeutics... Mehr lesen zu: Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA | ||||
| 30.04. | Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds | 27 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing potential best in
class oncology and CNS therapeutics... Mehr lesen zu: Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds | ||||
| 27.03. | Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting | 32 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced... Mehr lesen zu: Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting | ||||
| 13.03. | Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 | 25 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced... Mehr lesen zu: Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 | ||||
| 25.01. | Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds | 25 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing best in class
oncology and CNS therapeutics, today... Mehr lesen zu: Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds | ||||
| 18.01. | Rexahn Pharma Gets Approval For First Human Trial Of RX-3117 | 58 | AFX News | |
| PETAH TIKVA (dpa-AFX) - Rexahn Pharmaceuticals, Inc. (RNN) Wednesday said it
has secured approval in Hungary to initiate an exploratory first-in-human Phase
I clinical trial of RX-3117,... Mehr lesen zu: Rexahn Pharma Gets Approval For First Human Trial Of RX-3117 | ||||
| 18.01. | Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors | 24 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company developing and commercializing oncology and CNS
therapeutics, today announced that... Mehr lesen zu: Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors | ||||
| 17.01. | Rexahn Pharmaceuticals Provides Key Goals for 2012 | 27 | Business Wire | |
| Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing oncology and CNS therapeutics,
today provided guidance on its key... Mehr lesen zu: Rexahn Pharmaceuticals Provides Key Goals for 2012 | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
